Lyme Disease Vaccine Shows Promise in Clinical Trials
The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at healthcare company Baxter International S.A., revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States. Baxter conducted the clinical trial of the vaccine.
May 13, 2013 - 1:24:41 PM
Stony Brook Pharmacology Professor Receives Feldstein Medical Foundation Grant
Markus Seeliger, PhD, Assistant Professor in the Department of Pharmacological Sciences at Stony Brook University School of Medicine, has received a $60,000 grant from the Feldstein Medical Foundation to fund a project titled “New tools to hit moving targets in cancer therapy.” The purpose of the project is to use new computer technology to speed up the creation yet reduce the development cost of targeted cancer therapies.
Apr 23, 2013 - 4:11:56 PM
“Survival of the Fittest” Now Applies to Computers
Darwin’s theory of "survival of the fittest" originally referred to natural selection in biological systems, but new research from Brookhaven National Laboratory and Stony Brook University scientists shows that this evolutionary theory also applies to technological systems.
Apr 16, 2013 - 4:30:00 PM
Clinical Trials for Cellulite Treatment on the Horizon
Projected to start in the second half of 2013, researchers at Stony Brook University plan to begin phase IIa placebo-controlled clinical trials using a drug treatment method developed here to treat cellulite. The treatment method is licensed to BioSpecifics Technologies Corp. (“BSTC”), sublicensed to Auxilium Pharmaceuticals, Inc., (“Auxilium”), and uses clostridial collagenase histolyticum (“CCH”), an injectable form of the enzyme collagenase.
Apr 16, 2013 - 10:38:51 AM
SBU Professors Collaborate on NSF-Funded 'Materials Genome Initiative"
Three Stony Brook University researchers have been selected to receive an $800,000 Materials Genome Initiative (MGI) award from the National Science Foundation (NSF). The MGI is a multi-agency White House supported initiative whose goal is to reduce by half the current time and cost for transitioning breakthroughs from the laboratory to the marketplace – a process that can take as long as two decades.
Apr 15, 2013 - 2:00:00 PM
| | |
|
